• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to condensed heterocyclic compounds, in particular substances l of the general formula 9 cn + bcc-i-Shg Ngb H-CH-C - C C –C CH-SbH5BbB5TE “1. where n is 1 or 2; B is halogen or carboxyl; H is each independently H, halogen, C, -C-alkyl or C-C4-alkoxy, or their salts, which, as having activity on the gastrointestinal system, can be used in medicine. New substances have been obtained to reveal the pharmacological activity of bti. The process is carried out from 1,2,3,9-tetrahydro-9-oxo-pyrrole (or pyrido) -
    公开号:SU1279530A3
    申请号:SU3459054
    申请日:1982-06-29
    公开日:1986-12-23
    发明作者:Дориа Джанфедерико；Пассароти Карло；Аркари Джулиана
    申请人:Фармиталия Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:


    The invention relates to methods for the preparation of new substituted pyrrolyl pyrido (2,1-b) quinazolines or their salts, which have pharmacological properties that allow their use in medicine. The purpose of the invention is the synthesis of new compounds with valuable properties. Example 1. 2-Amino-isophthalic acid (27 g), dehydrated methanol (500 ml) and concentrated sulfuric acid (27 ml) are heated at 60 ° C for 20 hours. After cooling, the reaction mixture is evaporated in vacuo and the residue is discharged. Arivanes are diluted with ice / water. The precipitated product is filtered off and it is partitioned between chloroform and 5% NaHCO.j, the aqueous phase is separated, acidified with 37% HCt, the precipitated precipitate is recovered by filtration and washed with water to a neutral state. The resulting 1-methyl ester of 4-aminobenzene-1, 3-dicarboxylic acid with m.p. 224227 ° C (19.5 g) chemically interact with SOCij (18 ml) in benzene (ZOO ml) at reflux temperature for 3 hours. The solution is evaporated to dryness in vacuo, and the evaporation residue is dissolved in dioxane (300 ml), it chemically reacts with 2-pyrrolidinone (10.2 g) at room temperature for 20 hours. The precipitated product is filtered, washed with dioxane and then treated with NaHCO, resulting in 13 after filtration and washing with water. , 5 g of methyl ester 1,2,3,9-tetrahydro-9-occo pippo (2,1-b) quinazolin-7-carboxylic acid with m. Pl. 197-200 C, which reacts with benzaldehye, coma (17.5 g) in methanol (500 ml) in the presence of sodium methylate (6 g) with stirring for 3 hours. After cooling, the precipitate is filtered, washed with metnol to neutral . 14.8 g of 3-benzylidene-, 2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid methyl ester are obtained with a melting point of 25325 () °. C, which is heated in a mixture with 37% HCt - acetic acid in a ratio of: 1 (325 ml) with temea-i-yfre refluxing for an hour. As a result, 12.7 g of -benzylidene-1,2,3, 9-tetrahydro-9oxo-pyrrole (2,1-b) quinazoline-7-caronic acid, with mp. 285 287 ° С. Nuclear Magnetic Resonance Spectrum (CFjCOOD), ppm: 2.28 (S) (3N, CH,); 3, & 6 (t) (2I, -2 protons); 4.74 (t) (2H, C-1 protons); 7.40-7.85 (t) (4H, phenyl rotons); 8.09 (d) (IH, C-5 proton) ;, 8.65 (t) (IH, methine proton); 8.84 (dd) (1H, C-6 proton); 9.30 (d) (1H, C-8 proton). Carrying out the procedure in the same manner and using the appropriate substituted aldehydes, the following compounds are obtained: 3- (3-methyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrol (2,1-b) xi. Nasolin-7-carboxylic acid Art. square 319-32lC; 3- (4-methyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) chi - - - nazolin - / - carboxylic acid with m. Pl. (with decomposition) 340-350 C; 3- (2 55-dimesh-1-benzyl.en) -1, 2,3, 9 tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with so pl. 302-305 C; 3- (2,4-dimethyl-benzylnden) -1, 2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with m. Pl. 310-312s; 3- (3-methoxy-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with m.p. 325-327С; 3- (3-chlorobenzyl-1-schen) -1, 2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with m. Pl. 328-330C; 3- (2., 6-dichlorobenzylidene) -1.2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline - 7-carboxylic acid; lo acid with To mt 298-300 ° C; 3- (2-methyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with m. Pl. 285-287C; 3- (2,4-dichlorobenzylidene) -1,2,3,9 tetrahydro-9-oxo-pyrrole (2, -b) chi-nazolin-7-carboxylic acid with t. Sh1. 342-345 s; 3- (4-fluoro benzylidene) 152,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) hypazolin-7-carboxyethyl acid st. square (s. decomposition) 330 ° C
    Example 2. 2-Amino-5-chlorobenzoic acid (7.3 g) chemically reacts with SOCIj (9 ml) in benzene (50 ml) at reflux temperature for 3 hours. The solution is evaporated in a vacuum to dryness, the residual product of a solution in benzene (100 ml), it chemically reacts with 2-pyrrolidinone (4.26 g) at room temperature for 20 hours, the precipitated product is filtered off, washed with benzene, and then it is treated with an aqueous solution of NaHCOj. As a result, after filtration and washing with water until neutral, 5.1 g of 7-chloro-1,2,3,9-tetrahydropyrrole (2,1-b) quinazolin-9-one are obtained with m. 1sh. 173-175 C, which chemically reacts with benzaldehyde (7.2 g) in methanol (120 ml) in the presence of sodium methoxide (2.46 g) while stirring at room temperature for 20 T. The precipitated product is filtered off and washed with methanol and then with water until neutral. After crystallization from ethanol, 4.2 g of 3-benzylidene-7-chloro-1,2,3,9-tetragvadropyrrole (2,1-b) quinazolin-9-it is obtained, m.p. 225-227 С,
    Nuclear Magnetic Resonance Spectrum (CDCt,), S, ppm: 3.32 (a, t) (2H, C-2 protons) j 4.33 (t) (2H, C-1 protons); 7.47, 7 (t) (5H, phenyl protons); 7.68 (d) (2H, C-5 and C-6 protons); 7.88 (t) (1H, CH-); 8.28 (t) (C-8 proton).
    Carrying out the procedure in the same manner, the following compounds were prepared:
    7-chloro-3- (2-methyl-benzylidene) -1, 2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one with t. Pl. 227-230 ° C;
    7-chloro-3- (3-methyl-benzylidene) -1, 2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one with mp, 222-224 0;
    7-ishoop-3- (4-fluoropentane) -1, 2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one with m. Rai. 220-230 s (with decomposition);
    7-chloro-3- (2,6-dichlorobenzylidene) -1, 2.359-tetrahydro-pyrrole. (2,1-b) quinazolin-9-one, with m. Pl. 208-209 С;
    7-chloro-3- (2-methoxy-benzylidene), 2,3,9-tetrahydropyrrole (2,1-b) quinazolin-9-®n with t. Pl. 241-242 ° C;
    7-chloro-3- (3-methoxy-benzylidene) -1, 2,3,9-tetrahydropyrrole (2,1-b) quinazolin-9-one with m. Pl. 205-206 0;
    . 7-chloro-3- (3,4-dimethoxy-benzsh1Iden) -1,2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one with mp. 220-222 ° C;
    7-chloro-3- (2,3,4-grimethoxy-banzylidene) -1, 2,3,9-tetrahydropyrrole 2,1-b) quinazolin-9-one st. square 232 233 ° C;
    7-chloro-3- (2,4,5-trimethoxy-benzeneDen) -1,2,3,9-tetrahydro-pyrrole (2,1-b) quinazolk-9-one with m. Pl. 285286С |
    7-chloro-3- (3,4,5-trimethoxy-benzydiene) -1,2,3,9-t5trahydro-pyrrole - (2,1-b) quinazolin-9-one with m. Pl. 228229 ° C.
    Example 3. Compound 1-methyl zirfu 4-a cone of benzene-1, 3-dicarboxylic acid (12 g), obtained according to Example 1, chemically interacts with SOCt (9 ml) in benzene (200 ml) under a reflux temperature for 7 hours .
    The solution is allowed to dry in a vacuum to evaporate, the evaporation residue is dissolved in benzene (160 ml). This product chemically reacts with 2-piperidone (7.4 g) at room temperature for 20 hours.
    权利要求:
    Claims (1)
    [1]
    The precipitated precipitate is filtered, purified with acetone, then treated with an aqueous solution of sodium bicarbonate (NaHCOj), and as a result, after filtration and washing with water until neutral, 6 g of 6,7,8,9-tetrahydro-11-oxo methyl ester are obtained -11H-pyrido (2,1-b) quinazoline-2-carboxylic acid with m.p. 125-137 ° C, which chemically reacts with benzaldehyde (4.8 g) in methanol (100 ml) in the presence of sodium methoxide (3.72 g) with stirring and reflux temperature for 72 hours. After cooling, the reaction mixture is evaporated in vacuum and then acidified with 37% HCL-. . The precipitate formed is filtered off, washed with water until neutral, and crystallized from chloroform-ethanol mixture, as a result of which 2.9 g of 6-benzylidene-6, 7.8,9-tetrahydro-11-oxo-11H-pyrido are obtained (2.1 -B) quinazolium-2-carboxylic acid, with t. Pl. 288-290s. Nuclear Magnetic Resonance Spectrum (CFjCOOD) S, ppm: .2.37 (t) (2H, C-8 protons); 3.28 1 (m) (2H, C-7 protons); 4.46 (m) (211, C-9 protons); 7.69 (s) (5H, fep. Protons); 8.2 (d) (IH, C-4 proton); 8.20 (S) (IH, SP-); 8.86 (dd) (IH, C-3 proton); 9.30 (i) (IH, CI proton). Carrying out the procedure in the same way, the following compounds are obtained: 6- (2-methyl-benzylidene) -6 "7,8,9-tetrahydro-1 1 -oxo-11 H-pyrido (., - b) quinazoline -.- carboxylic acid with t. pl. 240-241 ° C; 6- (3-methyl-benzylidene) -6,7,8,9-tetrahydro-1-oxo-11H-pyrido (2,1-b) quinazoline-2-carboxylic acid, m.p. 283-285C; 6- (3-chlorobenzylidene) -6,7,8,9-tet ragidro-11-OXO-11H-pyrido (2,1-b) quinazoline-2-carboxylic acid, m, 264-26 b; 6- (2,6-dichlorobenzylidene) -6,7,8,9 -tetrahydro-1 1-oxo-11 H-pyrido (., 1-b) quinazoline-2-carboxylic acid with mp, (( with decomposition) 340 C; 5 „(4-fluoro-benzylidene) -6,7,8,9-tet rahydro-11-OXO-11H-pyrido (2,1-b) chi nasolin-2-carboxylic acid with m.p. 294-296 ° C. Example 4. 1,2,3,9-Tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid (1.4 g) chemically reacts with 2-methyl-benzal dehydrate (1, 65 g) in methanol (50 ml) in the presence of sodium methoxide (1.3 g while stirring at reflux temperature for 48 hours). After cooling, the reaction mixture is acidified with 37% HC. The resulting precipitate is filtered and washed with water to neutral After crystallization from a mixture of chloroform - ethanol, 1.2 g of 3- (2-methyl-be. unsylidene) -, 2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline are obtained. -7-carboxy acid Aim with mp 285 287 ° C. NMR spectrum (), ppm: 2.58 (S) (3N, CHj); 3.66 (m) (2H, C-2 protons); 4 , 74 (t) (2H, C-1 protons); 7.40-7.85 (w) (4H, phenyl protons); 8.09 (d) (1H, C-5 proton); 8.65 ( t) (IH, CH-); 8.84 (dd) (1H, C-6-proton); 9.30 (d) (IH, C-8 proton); Carrying out the procedure in the same way, compound 6- ( 2-methyl-benzylidene) -6,7,8,9-tetrahyd06 ro-11-OXO-1IH-pyrido (2,1-b) quinazoline-2-carboxylic acid with m, pl. 240-241 ° C. Example 5. 2-Amino-5-chlorobenzoic acid (5 g) chemically reacts with SOC., (2 ml) benzene (80 ml) at reflux temperature for. 6 hours. The solution is evaporated in vacuo to dryness, the evaporation residue is dissolved in benzene (SO 1CHP), it is chemically reacted with 2-piperidine (3.5 g) at room temperature for 40 hours. The precipitated product is filtered, washed with benzene, then treated with sodium bicarbonate (NaHCOj); as a result, after filtration and washing with water until neutral, 4 g of 2-chloro-6,7,8,9-tetrahydro, 1 1 H-pyri, co (2,1-b ) hinazolin-P-it with m. pl. which chemically reacts with benzaldehyde (6.3 g) in methanol (100 ml) in the presence of sodium methylate (2.75 g) while stirring at reflux temperature for 72 hours. After cooling, the reaction mixture is evaporated in BaKyjTsie, precipitated sediment filter. , are washed and washed with methanol, and then water until neutral, resulting in 4.6 g of 6-benzylidene-2-chloro-6, 7,8,9-tetrahydro-11H-pyrido (2,1-b) -11-she with m. Pl. 169 NMR spectrum (), ppm: 2.34 (t) (2H, C-8 protons); 3.25 (s) (2H, C-7 protons); 4.42 (br) (2H, C-9 protons); 7.62 (bg) (5H, phenyl protons); 7.90 (d) (iH, C-4 proton); 8.06 (bg) (1H, CH-); 8.08 (dd) (W, C-3 proton); 8.48 (w) (iH, C-1 proton). Example 6. A 4-methyl ester of 2-amino-benzene-1,4-dicarboxylic acid (10 g), prepared according to example 1, chemically reacts in 300.12 (9.4 ml) in half-distilled gel (300 ml) at a temperature reflux for 3 hours. This solution is evaporated in vacuo to dryness, the residual product is dissolved in dioxane (200 ml), it reacts chemically with 2-pyrrolidinone (5.2 g) at room temperature for 36 hours. The precipitate is filtered off, washed with dioxane and then treated with water 7 with a solution of TJaHCOj, the result of which after filtration and washing to neutrality with water is 5.9 g of methyl 1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-6- carboxylic acid with so pl. 134-136 ° C, which chemically reacts with benzaldehyde (3.8 g) in methanol (250 ml) in the presence of sodium methylate (1 g) with simultaneous stirring at a temperature of reflux, for 48 h. After cooling, the precipitate is filtered, washed with methanol and then dissolved in water; the solution is acidified with acetic acid and the precipitated precipitate is filtered, washed with water and crystallized from chloroform-ethanol to give 5 g of 3-benzylidene-1,2,3,9-tetrahydro 9-oxo-pyrrole (2,1-b a) quinazolin-6-carboxylic acid with m. pl. 382-384 0. NMR spectrum (CGDSOOB), 5 ppm: 3.71 (bt) (2H, C-2 protons); 4.78 (O (2H, C-1 protons); 7.72 (bz) (5H, phenyl protons); 8.31 (t) (IH, CH-); 8.57 Cdd (IH, C- 7 proton); 8.68 (d) (IH, C-8 proton); 8.71 (d) (IH, C-5 proton). Example 7. The 2-amino-benzene-1,4-dicarboxylic acid 4-methyl ester obtained according to Example 1 chemically reacts with (9 ml) in dioxane (30% ml) at reflux temperature for 4 hours. dry, the residual product is dissolved in dioxane (200 ml), it chemically reacts with 2-piperidine (7.4 g) at room temperature for 20 hours. The precipitate is filtered, washed with dioxane, after which it is treated with an aqueous solution of Shano ", As a result, after filtration and washing with water until neutral 6.6 g of 6,7,8,9-tetrahydro-11-oxo-11H-pyrido (2,1-b) quinazoline-3-carboxylic acid, methyl ester, with 6.6 g are obtained. 131-134 ° C, which chemically reacts with benzaldehyde (5.8 g) in methanol (200 ml) in the presence of sodium methoxide (4.12 g) while stirring at reflux temperature for 72 hours. After cooling, the evaporated precipitate is filtered and 308 is washed with methanol, and then it is dissolved in water: the solution is acidified with acetic acid and the precipitated precipitate is filtered, washed with water and crystallized from chloroform-methanol to give 2.6 g of 6-benzylidene-b, 7, 8,9-tetrahydro-11oxo-11H-pyrido (2,1-b) quinazoline-3-carboxylic acid with m. l. 233 235 ° C. Nuclear Magnetic Resonance Spectrum (CPDC), h / m: 2.37 (t) (2H, C-8 protons); 3.24 (t) (2H, C-7 protons); 4.43 (s) (2H, C-9 protons); 7.64 (s) (3H, phenyl protons); 8.12 (bs) (1H, CH-); 8.458, 75 (t) (3N, C-1, C-2 and C-4 protons). Example 8. Carrying out the procedure as in Examples 2 and 5 and using the corresponding 2-aminobenzoic acids as starting materials, the compound 3-benzylidene-6-chloro-1, 2,3,9-tetrahydro pyrrole (2,1-b) quinazoline is obtained -9-he with t. Pl. 238-240 ° C. Example 9. 3-Benzylidene-1, 2,3,9-tetrahydro-9-oxo-pyrrole (2, -b) quinazolin-7-carboxy acid, obtained in example 1, is treated with a stoichiometric amount of sodium methoxide in methanol at 60 ° C within 10 min. After evaporation in vacuo to a small volume, the resulting precipitate is filtered off, washed with a small amount of cold methanol and then with hexane. The sodium salt of 3-benzylidene-1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid with m.p., 300 ° C is obtained. The proposed compounds are preparations active on the gastrointestinal system, in particular, they have anti-ulcer and antisecretory effects, and are therefore used in medicine, for example, to prevent and treat ulcers, such as duodenal ulcers, stomach and esophagus, and to inhibit gastric acid secretion. In addition, these compounds are also used to reduce undesirable gastrointestinal side effects resulting from the systemic administration of anti-inflammatory prostaglandin synthetase inhibitors, and therefore can be used with these drugs for this purpose. 91 The anti-ulcer effect of the proposed compounds can be shown, for example, on the fact that they are active in restricted ulcer testing in rats according to well-known methods. The table shows, for example, the approximate value of EC anti-ulcer activity (effective dose for 50% of patients) when tested on rats of some of the proposed compounds after ingestion through the mouth. Known compounds, namely compound A: 6-chloro-1,2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one (t, pl. 187-190 s) and compound Bt 7- Methyl-1,2,3,9-tetrahydro-pyrrole (2,1-b) quinazolin-9-one (m.p. 170171 s) is synthesized and tested in rats in a manner similar to the proposed compound. Approximate ED values for compounds A and B are also listed in the table. From Table 1 it can be seen that the proposed compounds are much more active than the known ones. The test compound is administered into the body through a .mt (ro.) 1 hour before immobilization of the animals. For the experiment, six Sprague-Davtey male rats (weighing 100-120 g) 5 were not fed for 24 hours prior to the test. A square bending wire mesh with a small hole size is used for immobilization, and 4 hours after the immobilization of the rat, their stomach is cut out, their lesions are determined by means of a dissecting microscope. The proposed compounds also possess anti-secretory activity, as shown, for example, by the fact that they show activity after entering through the duodenum, inhibiting gastric secretion of rats, as determined by testing according to a known technique. For example, the 6-benzylidene-6,7,8,9-tetrahydro-11-OXO-11H-pyrido (2,1-b) quinazoline-3-carboxylic acid anti-secretory activity is estimated to be EDjo of about 15 mg / kg after entering this compound into the rat through the duodenum when tested according to the specified method. 0 Considering the fact that many anti-ulcer agents, such as atropine, possess significant, but undesirable acticholinergic activity, the proposed compounds are tested for antagonism against oxotremorine syndrome when tested on mice in accordance with the described method. When conducting this test, it was established that the proposed compounds have anti-cholinergic activity, such as the following compounds: 3-benzylidene-1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid ; 3-benzylidene-1., 2,3,9-tetrahydro-9 oxo-pyrrole (2,1-b) quinazoline-6-carboxylic acid; b-benzylidene-6,7,8,9-tetrahydro-11-oxy-11H-pyrido (2,1-b) quinazoline-2-carboxylic acid; 6-benzylidene-6,7,8,9-tetrahydro-11-OXO-1H-pyrido (2, -b) quinazoline-3-carboxylic acid does not show activity in the indicated test when administered through the mouth with a dose of 100 mg / kg In view of the high therapeutic index of the compounds proposed, they can be safely used in medicine. For example, the approximate acute toxicity (LDyg) of the following compounds: 3-benzylidene-1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid; 3-benzylidene-1, 2,3,9-tetrahydrog-9-oxo-pyrrole (2,1-b) quinazoline-6-carboxylic acid; 6-benzsh | nden-6,7,8,9-tetrahydro-11-oxo 1H-pyrido (2, i-b) quinazoline-2-carboxylic acid; 6-benzylidene-6,7,8.9-tetrahydro. " The f-11-OXO-11H-pyrido (2,1-b) quinazoline-3-carboxylic acid, measured on mice at a single injection of ever increasing doses and measured on the seventh day after the administration of the drug through the mouth, is more than 800 mg / kg Similar toxic effect data are also determined for other proposed compounds. Offered compounds can be introduced into the body and in the form of various dosage forms, for example, by mouth in the form of tablets, capsules, tablets. sugar or film coated liquid solutions or suspensions, through the rectum in the form of candles, parenterally, for example, by intramuscular or intravenous injection or infusion. The dose of the drug depends on the age, weight and conditions of the patient, as well as the method of administration of this drug. For example, the dosage for administering a drug through the mouth to an adult human body is in the range of 50-200 mg (single dose) and can be administered 1 to 5 times daily. The invention encompasses pharmaceutical compositions comprising the proposed compounds in combination with pharmaceutically acceptable medicinal media (which may be a carrier or diluent). Pharmaceutical compositions containing the inventive compounds are usually prepared by conventional methods and are administered to the body in the form of a pharmaceutically acceptable form. For example, solid forms of the preparation to be administered through the mouth may contain, along with the active compound, also diluents, for example, lactose, dextrose, sucrose, cellulose, corn starch, potato starch; lubricating agents, for example silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycols; binding agents, for example starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; disaggregating agents, for example starch, alginic acid, alginates or sodium glycol, derived from starch; gas vortex mixtures; coloring sweeteners; wetting agents such as lecithin polysorbates, lauryl sulfonates; and usually non-toxic and pharmacologically inactive substances intended for pharmaceutical formulations. These pharmaceutical preparations can be prepared in a known manner, for example by displacing, granulating, talting, sugar coating or film coating. Liquid dispersions to be administered through the mouth may, for example, be syrup, emulsions and suspensions. Syrups can contain 9 as a carrier (for example, sucrose or sucrose with glycerol and) or mannitol (s), or sorbitol, in particular syrup that is introduced into patients with diabetes, can contain only products that are not converted in the course of exchange. substances into glucose, or converted to glucose only in very small quantities. for example, sorbitol, suspensions and emulsions may contain as carrier, for example, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. Suspensions or solutions intended for intramuscular entry into the body may contain, along with the active compound, a pharmaceutically acceptable carrier, for example, a sterile isotonic aqueous solution of sodium chloride, olive oil, styloleate, glycols, for example propylene glycol, and, if desired, an appropriate amount of lidocaine hydrochloride. Solutions for intravenous injection or infusion may contain, for example, sterile water as a carrier, or preferably they may be in the form of aqueous isotonic solutions of common salt. Candles may contain, along with the active compound, a pharmaceutically acceptable carrier, for example cocoa butter, polyethylene glycol, a fatty acid ester and polyoxyethylene sorbitol as a surfactant or lecithin. Claims of Invention A method for producing substituted pyrrole- or pyrido (2,1-b) quinazolines of the general formula de n - 1 or 2; R is a halogen or carboxyl group; R is hydrogen; R ,, is hydrogen; B, Rj and R are each independently hydrogen, halogen, C | -C-alkoxy, or C, -C-alkyl group, their salts, characterized in that the compound of general formula 1 14 0 RJ and P3 have the indicated n, meaning, or its salt, | is reacted with an aldehyde of the formula where R, Rj and R have the indicated meanings, and allocate the desired product in free form or as a salt.
    2-Benzylidene-1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-7-carboxylic acid
    3-Benzylidene-1,2,3,9-tetrahydro-9-oxo-pyrrole (2,1-b) quinazoline-6-carboxylic acid
    6-Benzylidene-6,7,8,9-tetragyro-11-oxo-11H-pyrido (2, -b) quinazoline-2-carboxylic acid
    6-Benzylidene-6,7,8,9-tetrahydro-11-oxo-11H-pyrido (2,1-b) quinisoline-3-carboxylic acid
    Compound A Compound B
    3- (2,5-Dimethyl-benzsh1IDen) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) kinazolin-7-carboxylic acid
    3- (2,6-Dichlorobenzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinazoline-7-carboxylic acid
    3- (2-Methyl-benzylidene) -1 2 j 3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinazole-7-carboxylic acid
    3- (4-Methyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinazoline-7-carboxylic acid
    6- (4-Fluoro-ben-8-ilidene) -6,7,8,9-tetragndro-11-OXO-11H-pyrido (2,1-b) quinozoline-2-carboxylic acid
    ten
    eight
    73 54
    20 25 25 30 15
    1512795306
    3- (2,5-Dimethyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) xcnazoline-7-carboxylic acid
    3- (2,6-Dichlorobenzylidene) 1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,) quinazoline-7-carboxylic acid
    3- (2-Metsh1-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinaeroline-7-carboxylic acid
    3- (4-Metsh1-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinazoline-7-carboxylic acid
    6- (4-Fluoro-benzylidene 5-6,7,8,9-tetrahydro-11-OXO-1 H-pyrido (2, 1-b) chinazo-lin-2-carboxylic acid
    7-Chloro-3- (2-methyl-benzylidene) -1,2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b) quinazolin-9-one. . ,
    7-Chloro-3- (3,4,5-trimethoxy-benzylidene) -1, 2,3,9-tetrahydro-9-oxo-pyrrolo (2,1-b). Hinazolin-9-one
    Table continuation
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2136682C1|1999-09-10|Imidazopyridines, method of their synthesis, pharmaceutical composition on said and method of pharmaceutical composition preparing
    KR100668400B1|2007-01-17|Tetrahydropyridoethers
    CA1088073A|1980-10-21|Hydantoin therapeutic agents
    US4468400A|1984-08-28|Antiulcer tricyclic imidazo [1,2-a]pyridines
    SK27096A3|1996-12-04|Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids and pharmaceutical composition on their base
    JP2001526703A|2001-12-18|Condensed dihydropyran
    PT87988B|1995-05-04|PROCESS FOR THE PREPARATION OF DIAZOIS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
    EP0723544A1|1996-07-31|ALKOXY ALKYL CARBAMATES FROM IMIDAZO |PYRIDINES
    SU1279530A3|1986-12-23|Method of producing substituted pyrrole or pyrido | quinozalines or salts thereof
    EP0172608A1|1986-02-26|Novel triazine derivative, process for preparing same and pharmaceutical preparations containing same
    JP2001503759A|2001-03-21|3-carboxamide derivative of 5H-pyrrolo [2,1-c] [1,4] benzodiazepine
    US4168380A|1979-09-18|7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
    SU999973A3|1983-02-23|Process for producing derivatives of pyrido|pyrimidine or their pharmaceutically acceptable salts or their optically active isomers
    WO1992006979A1|1992-04-30|New diazines
    CS244107B2|1986-07-17|Method of substituted pyrdoido-|pyrimidines production
    US4442289A|1984-04-10|4-Oxothieno[3,2-d]pyrimidine acetic acid esters
    US4124712A|1978-11-07|Ergot peptide alkaloid derivatives
    HU186951B|1985-10-28|Process for producing substitited thizaolo-bracket-3,2-a-bracket closed-parimidines and pharmaceutical compositions containing them
    JPH10505333A|1998-05-26|Imidazopyridine-azolidinone
    PL80112B1|1975-08-30|
    FR2593179A1|1987-07-24|IMIDAZO | QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
    KR900003392B1|1990-05-18|Spiro-|-fluoro fluoren derivatives
    FR2520742A1|1983-08-05|SUBSTITUTED 1,3,4-THIADIAZOLO | PYRIMIDINES USEFUL AS MEDICAMENTS AND PROCESS FOR THEIR PREPARATION
    WO1996003402A1|1996-02-08|Halogenated imidazopyridines
    KR860000200B1|1986-03-03|Process for preparing spiro compounds
    同族专利:
    公开号 | 公开日
    FR2508457B1|1985-08-30|
    ZA824502B|1983-04-27|
    DK292782A|1982-12-31|
    GB2103207A|1983-02-16|
    CA1183135A|1985-02-26|
    ATA247582A|1986-01-15|
    FI822329L|1982-12-31|
    FI73997C|1987-12-10|
    SE8204034L|1982-12-31|
    SE8204034D0|1982-06-29|
    BE893694A|1982-12-29|
    SE448096B|1987-01-19|
    DE3224213A1|1983-01-27|
    IL66146D0|1982-09-30|
    JPS588082A|1983-01-18|
    NL8202602A|1983-01-17|
    AU552065B2|1986-05-22|
    AT377586B|1985-04-10|
    FR2508457A1|1982-12-31|
    FI73997B|1987-08-31|
    IT1159069B|1987-02-25|
    IL66146A|1985-12-31|
    GB2103207B|1985-01-09|
    IT8222005D0|1982-06-23|
    ATA775378A|1984-08-15|
    SU1279530A1|1986-12-23|
    AT381092B|1986-08-25|
    FI822329A0|1982-06-30|
    AU8492282A|1983-01-06|
    CH657618A5|1986-09-15|
    US4428952A|1984-01-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2992221A|1958-07-03|1961-07-11|Petersen Siegfried|Polymethylene-oxoquinazolines and their production|
    US3271396A|1964-08-17|1966-09-06|Squibb & Sons Inc|Pyrido-quinazoline derivatives|
    DE1670416A1|1966-12-30|1971-02-11|Chem Fab Von Heyden Gmbh Muenc|Process for the preparation of amino-substituted quinazolinone derivatives|
    HU174693B|1976-02-12|1980-03-28|Chinoin Gyogyszer Es Vegyeszet|Process for producing condensed pyrimidine derivatives|
    DE2739020A1|1977-08-26|1979-03-01|Schering Ag|Pyrido--quinazolin-11-one derivs. - useful as antiinflammatories, antipyretics, analgesics and antiallergics|
    US4310526A|1979-05-08|1982-01-12|Farmitalia Carlo Erba S.P.A.|Substituted 6,7-methylene pyrido[1,2-a]pyrimidines useful as anti-allergic and anti-ulcer agents|
    HU183173B|1980-06-24|1984-04-28|Chinoin Gyogyszer Es Vegyeszet|Process for producing 6-hydrazono-pyrido-aracket-2,1-b-bracket closed-quinazolin-11-ones|
    JP5277093B2|2009-07-07|2013-08-28|株式会社Ｋｄｄｉ研究所|Method and system for establishing session between access points using SIP server|US4537962A|1982-02-04|1985-08-27|Farmitalia Carlo Erba, S.P.A.|Substituted 1,3,4-thiadiazolo[3,2-A]pyrimidines and compositions containing them|
    ES8406476A1|1982-04-29|1984-07-01|Erba Farmitalia|Condensed cycloaliphatic derivatives of substituted pyrido[1,2-a]pyrimidines and methods of treating allergic conditions, peptic ulcers and inhibiting gastric acid secretion with them|
    ES524262A0|1982-08-05|1984-11-16|Erba Farmitalia|"PROCEDURE FOR PREPARING QUINAZOLINE DERIVATIVES"|
    HUT66324A|1991-07-29|1994-11-28|Warner Lambert Co|Quinazoline derivatives as acetylcholinesterase inhibitors and pharmaceutical compositions containing them|
    KR20030025235A|2000-06-07|2003-03-28|버텍스 파마슈티칼스 인코포레이티드|Caspase inhibitors and uses thereof|
    WO2019028357A1|2017-08-03|2019-02-07|Galectin Sciences, Llc|Compounds for the prevention and treatment of medical disorders and uses thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8120126|1981-06-30|
    [返回顶部]